UBS says the focus on Gilead Sciences, Inc. GILD is shifting to NASH amid weaker HCV sales. The brokerage maintains its Buy rating, as it remains encouraged by the top-line ' 4997 data in NASH and the company's plan to enter Phase 3 in the first quarter 2017 with combo studies beginning in mid-2017.
“We continue to believe that the NASH (non-alcoholic steatohepatitis) franchise is well-positioned to address the large market opportunity,” analyst Marc Goodman wrote in a note.
Goodman cut his total 2016 HCV estimates by $954 million to $15.3 billion after HCV sales globally fell 17 percent sequentially for the third quarter. Gilead reported third-quarter top-line product sales in line but missed on the bottom line by $0.11 on higher costs and taxes.
However, the company’s HIV sales came $190 million above consensus of $431 million.
Goodman reiterated his $118 price target on the stock, which was down 1.51 percent to $72.95 at last check.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.